CRNX - Crinetics Pharmaceuticals, Inc.
| Previous Close | 16.34 |
| Open | 16.34 |
| Bid | 11.00 x 2900 |
| Ask | 0.00 x 900 |
| Day's Range | 15.05 - 16.34 |
| 52 Week Range | 10.63 - 28.81 |
| Volume | 199,944 |
| Avg. Volume | 143,207 |
| Market Cap | 518.632M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings Date | May 08, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.80 |
- GlobeNewswire
Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Adriana Cabré, MBA, as Vice President of Human Resources. “We are pleased to welcome Adriana to the executive team to lead our Human Resource function,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.
- Zacks
Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now?
Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. “So far, 2020 has proven to be a transformational time for Crinetics, highlighted by the positive interim Phase 2 results for paltusotine, our lead product candidate for the treatment of acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.
- GlobeNewswire
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has closed its previously announced underwritten public offering of 8,222,500 shares of its common stock, including 1,072,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $14.00 per share. Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine and its other research and development programs, and for working capital and general corporate purposes. The securities described above were offered by Crinetics pursuant to a shelf registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC).
- Zacks
Crinetics Pharmaceuticals, Inc. (CRNX) Upgraded to Buy: Here's What You Should Know
Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares to be sold in the offering are being sold by Crinetics. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,072,500 shares of common stock.
- GlobeNewswire
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics.
- GlobeNewswire
Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update
Data from initial patients who have completed the ongoing open label Edge trial show that IGF-1 levels were maintained after 13 weeks of treatment when patients were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands, octreotide or lanreotide. Results as of a February 23, 2020 data cutoff showed that acromegaly patients switching from injectable depot therapy to once daily oral paltusotine (formerly CRN00808) maintained IGF-1 levels previously achieved with commercially available depot injections of somatostatin receptor ligands (SRLs).
- GlobeNewswire
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
SAN DIEGO, March 09, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Zacks
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 19, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Simply Wall St.
Those Who Purchased Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares A Year Ago Have A 11% Loss To Show For It
While not a mind-blowing move, it is good to see that the Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) share price...
- GlobeNewswire
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 08, 2020 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 26, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Zacks
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -11.11% and 51.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 12, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Zacks
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
We're Not Very Worried About Crinetics Pharmaceuticals's (NASDAQ:CRNX) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
SAN DIEGO, Sept. 25, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Zacks
What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?
Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- GlobeNewswire
Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 03, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Zacks
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Simply Wall St.
If You Had Bought Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
- GlobeNewswire
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it would receive up to approximately $0.9 million in continued funding under its Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) of the National Institutes of Health (NIH). The funds are being used to support the ongoing research and development of Crinetics’ nonpeptide somatostatin agonists for congenital hyperinsulinemias (CHI).
